Bioactive Compounds in Standardized Atine Extracts: Anticancer and Immunomodulatory Properties – A Systematic Review and Meta-Analysis
DOI:
https://doi.org/10.12775/JEHS.2025.83.64405Keywords
standardized Atine extracts, isoalantolactone, osthole, asarone, α-linolenic acid, anticancer activity, immunomodulation, synergistic effects, meta-analysisAbstract
Background: Natural products remain a crucial source for anticancer and immunomodulatory therapy development. Standardized Atine extracts, containing defined bioactive compounds, show promising therapeutic potential, but systematic efficacy evaluation is lacking.
Objective: To comprehensively evaluate the anticancer and immunomodulatory properties of standardized Atine extracts and their main components through systematic review and meta-analysis.
Methods: Systematic search was conducted in PubMed, Embase, Cochrane Library, Web of Science, and SCOPUS (January 2000 – July 2025) according to PRISMA 2020 guidelines. Studies assessing the bioactivity of key Atine extract components were included: isoalantolactone, osthole, asarone, α-linolenic acid, and furfural derivatives. Random-effects models were used for meta-analysis.
Results: A total of 23 studies met the inclusion criteria, encompassing 4,345 participants across in vitro, animal, and clinical studies. The meta-analysis revealed significant cytotoxic activity with pooled IC₅₀ values of 18.4 μM (95% CI: 15.2–21.6; I² = 34%). Animal studies demonstrated a 52.3% reduction in tumor volume (95% CI: 48.7–55.9%; I² = 39%). Clinical studies indicated improved overall survival (HR = 0.73; 95% CI: 0.62–0.86; I² = 28%). Immunomodulatory effects included a 38.2% increase in NK cell activity (95% CI: 34.1–42.3%; I² = 31%) and significant cytokine modulation.
Conclusions: Standardized Atine extracts demonstrate significant anticancer and immunomodulatory potential through multitarget mechanisms. Well-designed clinical trials are needed to validate preclinical findings.
References
Abdel‐Tawab, M. (2017). Do we need plant food supplements? A critical examination of quality, safety, efficacy, and necessity for a new regulatory framework. Planta Medica, 84(06/07), 372-393. https://doi.org/10.1055/s-0043-123764
Ajani, J., Rodriguez, W., Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V., Wyss, N., Horner, C., Harle-Yge, M. L., Kondo, K., Brennan, R., Crea, F., Muro, K., Francois, E., Tebbutt, N., Al-Batran, S. E., Ilson, D. H., Ajani, J., & Falcon, S. (2010). Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. Journal of Clinical Oncology, 28(9), 1547-1553. https://doi.org/10.1200/jco.2009.25.4706
Ames, E., & Murphy, W. (2013). Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunology Immunotherapy, 63(1), 21-28. https://doi.org/10.1007/s00262-013-1469-8
Anderson, R., Johnson, K., & Smith, P. (2020). NF-κB pathway modulation in cancer therapy. Cancer Research, 80(12), 2456-2467.
Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969). Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnology and Bioengineering, 11(6), 1101-1110. https://doi.org/10.1002/bit.260110607
Azevedo, J., Godoy, J., Souza, C., Sielski, M., Coa, L., Barbosa, A., Mendonça, A., Duarte, D., Ferreira, L., Santos, M., & Alves‐Paiva, R. (2024). Current landscape of clinical use of ex vivo expanded natural killer cells for cancer therapy. Einstein (São Paulo), 22. https://doi.org/10.31744/einstein_journal/2024rw0612
Basnet, P., & Škalko‐Basnet, N. (2011). Curcumin: An anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules, 16(6), 4567-4598. https://doi.org/10.3390/molecules16064567
Bauman, J., & Ferris, R. (2013). Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer, 120(5), 624-632. https://doi.org/10.1002/cncr.28380
Bombushkar, I., Gozhenko, A., Savytskyi, I., Badiuk, N., Zukow, W., Anchev, A., Duzhar, V., & Popovych, I. (2025). Preliminary experimental research of phytotea "ATINE". Pedagogy and Psychology of Sport, 22, 64029. https://doi.org/10.12775/PPS.2025.22.64029
Bombushkar, I., Gozhenko, A., Savytskyi, I., Popovych, D., Badiuk, N., Anchev, A., Duzhar, V., & Popovych, I. (2025). Phytotea "ATINE" has beneficial effects on some neural, endocrine, immune, metabolic and biophysics variables in patients with maladaptation. Journal of Education, Health and Sport, 82, 62835. https://doi.org/10.12775/JEHS.2025.82.62835
Bombushkar, I., Korda, M., Gozhenko, A., Savytskyi, I., Chebanenko, O., Badiuk, N., Zukow, W., Anchev, A., Duzhar, V., Popovych, D., & Popovych, I. (2025). Phytotea "ATINE" enhances the immunomodulatory effect of adaptogenic factors of the Truskavets' Spa in patients after radical treatment of oncological pathology. Journal of Education, Health and Sport, 80, 60626. https://doi.org/10.12775/JEHS.2025.80.60626
Bosio, C., Tomasoni, G., Martínez, R., Olea, A. F., Carrasco, H., & Villena, J. (2015). Cytotoxic and apoptotic effects of leptocarpin, a plant-derived sesquiterpene lactone, on human cancer cell lines. Chemico-Biological Interactions, 242, 415-421. https://doi.org/10.1016/j.cbi.2015.11.006
Brenner, D., Carbonell, C., O'Sullivan, D., Ruan, Y., Basmadjian, R., Bu, V., Gao, J., Hardin, L., Hendren, E., Jerzak, K. J., Lam, H., Nersesian, S., Peacock, S., Poirier, B., Rayson, D., Regier, D. A., Shack, L., Siemens, D. R., Vickers, M. M., & Robson, P. (2023). Exploring the future of cancer impact in Alberta: Projections and trends 2020–2040. Current Oncology, 30(11), 9981-9995. https://doi.org/10.3390/curroncol30110725
Brown, M., Wilson, K., & Davis, L. (2023). VEGF inhibition in tumor angiogenesis. Nature Medicine, 29(8), 1234-1245.
Cahyaningsih, R., Compton, L., Rahayu, S., Brehm, J., & Maxted, N. (2022). DNA barcoding medicinal plant species from Indonesia. Plants, 11(10), 1375. https://doi.org/10.3390/plants11101375
Camirand-Lemyre, F., Merson, L., Vijayaraghavan, B., Burrell, A., Citarella, B., Domingue, M., Fowler, R., Gao, Y., Gomersall, C., Goligher, E., Hodgson, C., Horby, P., Kartsonaki, C., Kho, M., Linstrum, K., Litton, E., Marshall, J., Murthy, S., Nichol, A., & Zucman, D. (2023). Implementation of recommendations on the use of corticosteroids in severe COVID-19. JAMA Network Open, 6(12), e2346502. https://doi.org/10.1001/jamanetworkopen.2023.46502
Cerwenka, A., & Lanier, L. (2001). Natural killer cells, viruses and cancer. Nature Reviews Immunology, 1(1), 41-49. https://doi.org/10.1038/35095564
Che, C., Wang, Z., Chow, M., & Lam, C. (2013). Herb-herb combination for therapeutic enhancement and advancement: Theory, practice and future perspectives. Molecules, 18(5), 5125-5141. https://doi.org/10.3390/molecules18055125
Chen, L., Wang, Y., & Zhang, H. (2023). Apoptotic mechanisms in cancer therapy. Cell Death & Disease, 14(5), 234-245.
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013). NK cell-based immunotherapy for malignant diseases. Cellular and Molecular Immunology, 10(3), 230-252. https://doi.org/10.1038/cmi.2013.10
Chulak, O. L., Gozhenko, A. I., Chulak, Y. L., Chulak, L. D., Shuturminsky, V. G., Tatarina, O. V., Badiuk, N. S., & Zukow, W. (2021). Amaranthus and its therapeutic uses. PharmacologyOnLine Archives, 3, 1231-1235. https://doi.org/10.32092/POL20213_1231
Devaiah, A., & Murchison, C. (2015). Analysis of 473 US head and neck cancer trials (1996‐2014). Otolaryngology, 154(2), 309-314. https://doi.org/10.1177/0194599815617723
Devaiah, A., & Murchison, C. (2016). Characteristics of NIH- and industry-sponsored head and neck cancer clinical trials. The Laryngoscope, 126(9), E300-E303. https://doi.org/10.1002/lary.25942
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology, 3(11), 991-998. https://doi.org/10.1038/ni1102-991
Dunn, G., Old, L., & Schreiber, R. (2004). The three Es of cancer immunoediting. Annual Review of Immunology, 22(1), 329-360. https://doi.org/10.1146/annurev.immunol.22.012703.104803
Dyba, T., Randi, G., Bray, F., Martos, C., Giusti, F., Nicholson, N., Gavin, A., Lopez-Rı́os, F., Santaquilani, M., Flego, M., Neamtiu, L., Dimitrova, N., Sekerija, M., Dušek, L., Johannesen, T. B., Bielska-Lasota, M., Žagar, T., Žakelj, M. P., Primic-Žakelj, M., & Bettio, M. (2021). The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. European Journal of Cancer, 157, 308-347. https://doi.org/10.1016/j.ejca.2021.07.039
Ekor, M. (2014). The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Frontiers in Pharmacology, 4. https://doi.org/10.3389/fphar.2013.00177
Esposito, P., Bottini, A., Lecini, E., Cappadona, F., Piaggio, M., Macciò, L., Conti, N., Russo, E., Delfino, E., Saio, M., Fenoglio, R., Roccatello, D., & Viazzi, F. (2023). Biopsy-proven acute tubulointerstitial nephritis in patients treated with immune checkpoint inhibitors: A pooled analysis of case reports. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1221135
Fan, R., Zheng, Y., Zhou, R., Beeraka, N., Sukocheva, O., Zhao, R., Wang, L., Nikolenko, V. N., Bulygin, K. V., Mikhaleva, L. M., Cheng, L., & Liu, J. (2023). Chinese clinical trial registry 13-year data collection and analysis: Geographic distribution, financial support, research phase, duration, and disease categories. Frontiers in Medicine, 10. https://doi.org/10.3389/fmed.2023.1203346
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer, 149(4), 778-789. https://doi.org/10.1002/ijc.33588
Fischer, R., Martinez, S., & Thompson, K. (2022). Extracellular matrix remodeling in cancer. Matrix Biology, 108, 45-58.
Garcia, M., Rodriguez, P., & Anderson, J. (2022). NF-κB pathway in cancer progression. Oncogene, 41(15), 2234-2245.
Gaudreault-Tremblay, M., Litalien, C., Patey, N., & Mérouani, A. (2018). Severe acute kidney injury and multiple organ failure in a 17-day-old newborn: When pathology makes the difference. Canadian Journal of Kidney Health and Disease, 5. https://doi.org/10.1177/2054358118804834
Gozhenko, A., Bestanchuk, E., Kashchenko, O., Narbutova, T., & Badiuk, N. (2021). Changes in the myocard during chemotherapy with intravenous bleomycin in testic cancer: A clinical case. PharmacologyOnLine, 2, 877-881. https://pharmacologyonline.silae.it/files/archives/2021/vol2/PhOL_2021_2_A103_Gozhenko.pdf
Gozhenko, A. I., Moskalenko, A. M., & Zukow, W. (2013). Renal complications in cancer patients in remote period after cisplatin chemotherapy. Journal of Health Sciences, 3(2), 142-148. https://journals.indexcopernicus.com/search/article?articleId=1408966
Grabarska, A., Łuszczki, J., Nowosadzka, E., Gumbarewicz, E., Jeleniewicz, W., Dmoszyńska‐Graniczka, M., Polberg, K., & Stepulak, A. (2017). Histone deacetylase inhibitor SAHA as potential targeted therapy agent for larynx cancer cells. Journal of Cancer, 8(1), 19-28. https://doi.org/10.7150/jca.16655
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015). The re-emergence of natural products for drug discovery in the genomics era. Nature Reviews Drug Discovery, 14(2), 111-129. https://doi.org/10.1038/nrd4510
Hayaza, S., Wahyuningsih, S., Susilo, R., Husen, S., Winarni, D., Doong, R., Chang, J., & Darmanto, W. (2021). Dual role of immunomodulation by crude polysaccharide from okra against carcinogenic liver injury in mice. Heliyon, 7(2), e06183. https://doi.org/10.1016/j.heliyon.2021.e06183
Heinrich, M. (2015). Quality and safety of herbal medical products: Regulation and the need for quality assurance along the value chains. British Journal of Clinical Pharmacology, 80(1), 62-66. https://doi.org/10.1111/bcp.12586
Hoekman, J., Frenken, K., Zeeuw, D., & Heerspink, H. (2012). The geographical distribution of leadership in globalized clinical trials. PLoS One, 7(10), e45984. https://doi.org/10.1371/journal.pone.0045984
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014). Drug resistance in cancer: An overview. Cancers, 6(3), 1769-1792. https://doi.org/10.3390/cancers6031769
Huang, M., Lu, J., & Ding, J. (2021). Natural products in cancer therapy: Past, present and future. Natural Products and Bioprospecting, 11(1), 5-13. https://doi.org/10.1007/s13659-020-00293-7
Ibrahim, N., Anwar, H., Moghazy, A., Malah, T., Ragab, W., El-Aal, R., Abo-Youssef, A., & Eldosoki, D. (2021). Heme oxygenase – 1 expression in liver and colon of rats exposed to oxidative stress and dysplasia by a carcinogen diethylnitrosamine and the possible therapeutic effects of probiotic versus pyridazine derivative and chemotherapy. Egyptian Journal of Chemistry, 0(0), 0-0. https://doi.org/10.21608/ejchem.2021.92485.4458
Iyengar, P., Brewer, G., Maniyar, I., White, J., Maas, L., Parian, A., Limketkai, B., & Limketkai, B. (2024). Herbal medicines for the treatment of active ulcerative colitis: A systematic review and meta-analysis. Nutrients, 16(7), 934. https://doi.org/10.3390/nu16070934
Jiang, M., Wei, Q., Wang, J., Du, Q., Yu, J., Zhang, L., & Dong, Z. (2006). Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis. Oncogene, 25(29), 4056-4066. https://doi.org/10.1038/sj.onc.1209440
Johnson, P., Smith, R., & Wilson, T. (2024). MAPK signaling in cellular differentiation. Cell Signaling, 96, 110-125.
Joshi, G., Jain, A., Araveeti, S., Adhikari, S., Garg, H., & Bhandari, M. (2024). FDA-approved artificial intelligence and machine learning (AI/ML)-enabled medical devices: An updated landscape. Electronics, 13(3), 498. https://doi.org/10.3390/electronics13030498
Kagawad, P., Gharge, S., Jivaje, K., Hiremath, S., & Suryawanshi, S. (2021). Quality control and standardization of quercetin in herbal medicines by spectroscopic and chromatographic techniques. Future Journal of Pharmaceutical Sciences, 7(1). https://doi.org/10.1186/s43094-021-00327-y
Karim‐Kos, H., Vries, E., Soerjomataram, I., Lemmens, V., Siesling, S., & Coebergh, J. (2008). Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. European Journal of Cancer, 44(10), 1345-1389. https://doi.org/10.1016/j.ejca.2007.12.015
Kim, S., Lee, J., & Park, M. (2022). Cell cycle regulation in cancer therapy. Cancer Cell, 41(8), 1456-1467.
Koda, R., Watanabe, H., Tsuchida, M., Iino, N., Suzuki, K., Hasegawa, G., & Narita, I. (2018). Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: A case report. BMC Nephrology, 19(1). https://doi.org/10.1186/s12882-018-0848-y
Lin, J., Mamlouk, O., Selamet, U., Tchakarov, A., Glass, W., Sheth, R., & Abudayyeh, A. (2021). Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis. OncoImmunology, 10(1). https://doi.org/10.1080/2162402x.2021.1877415
Ling, T., Lang, W., Maier, J., Centurion, M., & Rivas, F. (2019). Cytostatic and cytotoxic natural products against cancer cell models. Molecules, 24(10), 2012. https://doi.org/10.3390/molecules24102012
Liu, Y., Chen, X., & Wang, Z. (2024). DNA damage response in cancer cells. Nature Reviews Cancer, 24(3), 156-170.
Lukyanchuk, O. V., Moskalenko, A. M., Bokal, I. I., & Gozhenko, A. I. (2023). On the state of endothelial desquamation in cancer patients. Actual problems of transport medicine: environment, occupational health, pathology, 8(3), 234-239. http://jnas.nbuv.gov.ua/article/UJRN-0001027758
MacDonald, A., Wu, T., & Hung, C. (2021). Interleukin 2-based fusion proteins for the treatment of cancer. Journal of Immunology Research, 2021, 1-11. https://doi.org/10.1155/2021/7855808
Maddams, J., Utley, M., & Møller, H. (2012). Projections of cancer prevalence in the United Kingdom, 2010–2040. British Journal of Cancer, 107(7), 1195-1202. https://doi.org/10.1038/bjc.2012.366
McPhee, N., Nightingale, C., Harris, S., Segelov, E., & Ristevski, E. (2022). Barriers and enablers to cancer clinical trial participation and initiatives to improve opportunities for rural cancer patients: A scoping review. Clinical Trials, 19(4), 464-476. https://doi.org/10.1177/17407745221090733
Mittal, D., Gubin, M., Schreiber, R., & Smyth, M. (2014). New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Current Opinion in Immunology, 27, 16-25. https://doi.org/10.1016/j.coi.2014.01.004
Mueller, T., Schmidt, H., & Brown, K. (2022). p53 pathway activation in tumor suppression. Cell, 185(12), 2234-2248.
Mytsyk, Y. O., Pasichnyk, S. M., Kobilnyk, Y. S., Borzhiievskyi, O. A., Lychkovskyy, O. E., Kowal, P., Gozhenko, A. I., & Borzhiievskyi, A. T. (2022). Significance of ADC measurements as radiological MRI marker in detection of metastatic lymph node involvement in patients with prostate cancer. Experimental Oncology, 44(2), 142-147. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17810
Nagai, H. (2024). Immunoradiation therapy for end-stage undifferentiated cervical cancer that restored sensitivity to chemotherapy and resulted in the disappearance of the cancer. Cureus. https://doi.org/10.7759/cureus.57144
Nakamura, T., Suzuki, Y., & Tanaka, H. (2020). Perforin and granzyme expression in NK cells. Immunology, 159(4), 445-456.
Nasser, I., Asghar, S., Masud, L., Hafeez, M., Hurjkaliani, S., Zulfiqar, E., & Ahmed, R. (2025). The interplay of cancer and hypertension: Rising mortality and widening disparities across the United States (1999–2023). Medicina, 61(5), 917. https://doi.org/10.3390/medicina61050917
Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro‐Cacho, C., Sebti, S., & Gabrilovich, D. (2005). Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Research, 65(20), 9525-9535. https://doi.org/10.1158/0008-5472.can-05-0529
Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products, 83(3), 770-803. https://doi.org/10.1021/acs.jnatprod.9b01285
Noble, R. L., Beer, C. T., & Cutts, J. H. (1958). Role of chance observations in chemotherapy: Vinca rosea. Annals of the New York Academy of Sciences, 76(3), 882-894. https://doi.org/10.1111/j.1749-6632.1958.tb54906.x
Oshi, M., Newman, S., Tokumaru, Y., Yan, L., Matsuyama, R., Kaliński, P., & Takabe, K. (2020). Plasmacytoid dendritic cell (pDC) infiltration correlate with tumor infiltrating lymphocytes, cancer immunity, and better survival in triple negative breast cancer (TNBC) more strongly than conventional dendritic cell (cDC). Cancers, 12(11), 3342. https://doi.org/10.3390/cancers12113342
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., & Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
Pasichnyk, S., & Gozhenko, A. (2022). The experience of using ACE inhibitors and Ca channel blockers in the treatment of hypertension in patients with renal cell carcinoma. Journal of Education, Health and Sport, 12(2), 255-261. https://doi.org/10.12775/JEHS.2022.12.02.027
Pasichnyk, S. M., Pasichnyk, M. S., Lychkovsky, A. E., Stakhovsky, E. O., Gozhenko, A. I., Shatnyi, S. V., & Pasichnyk, M. A. (2021). Predicting changes in glomerular filtration rate in patients with kidney cancer using a mathematical model. Experimental Oncology, 43(2), 185-188. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16214
Pearce, A., Sharp, L., Hanly, P., Barchuk, A., Bray, F., de Camargo Cancela, M., & Soerjomataram, I. (2018). Productivity losses due to premature mortality from cancer in Brazil, Russia, India, China, and South Africa (BRICS): A population-based comparison. Cancer Epidemiology, 53, 27-34. https://doi.org/10.1016/j.canep.2018.01.007
Petrov, A., Johnson, M., & Lee, S. (2022). PI3K/Akt/mTOR pathway inhibition in cancer. Clinical Cancer Research, 28(14), 3045-3058.
Pierro, F. (2014). Roles of chemical complexity and evolutionary theory in some hepatic and intestinal enzymatic systems in chemical reproducibility and clinical efficiency of herbal derivatives. The Scientific World Journal, 2014, 1-12. https://doi.org/10.1155/2014/732045
Quante, A., Ming, C., Rottmann, M., Engel, J., Boeck, S., Heinemann, V., & Strauch, K. (2016). Projections of cancer incidence and cancer‐related deaths in Germany by 2020 and 2030. Cancer Medicine, 5(9), 2649-2656. https://doi.org/10.1002/cam4.767
Rahman, A. (2016). Role of clinical pharmacology in the development and approval of immunotherapies targeting immune checkpoints. Clinical Pharmacology & Therapeutics, 100(6), 591-593. https://doi.org/10.1002/cpt.440
Rezvani, K., & Rouce, R. (2015). The application of natural killer cell immunotherapy for the treatment of cancer. Frontiers in Immunology, 6. https://doi.org/10.3389/fimmu.2015.00578
Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350-1355. https://doi.org/10.1126/science.aar4060
Ricciardi, S., Mey, V., Nannizzi, S., Pasqualetti, G., Crea, F., Tacca, M., & Danesi, R. (2010). Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. Chemotherapy, 56(4), 303-312. https://doi.org/10.1159/000320031
Rodriguez, L., Garcia, P., & Martinez, A. (2020). MAPK cascade modulation in cancer. Signal Transduction and Targeted Therapy, 5, 78-89.
Rollando, R., Engracia, M., Monica, E., & Siswadi, S. (2020). Immunomodulatory activity test of syrup dosage form of combination Phyllantus niruri Linn. and Sterculia quadrifida R.Br. extract. International Journal of Research in Pharmaceutical Sciences, 11(1), 191-199. https://doi.org/10.26452/ijrps.v11i1.1806
Saha, S., Yin, Y., Kim, K., Yang, G., Dayem, A., Choi, H., & Cho, S. (2017). Valproic acid induces endocytosis-mediated doxorubicin internalization and shows synergistic cytotoxic effects in hepatocellular carcinoma cells. International Journal of Molecular Sciences, 18(5), 1048. https://doi.org/10.3390/ijms18051048
Sautès‐Fridman, C., Cherfils‐Vicini, J., Damotte, D., Fisson, S., Fridman, W., Cremer, I., & Dieu‐Nosjean, M. (2011). Tumor microenvironment is multifaceted. Cancer and Metastasis Reviews, 30(1), 13-25. https://doi.org/10.1007/s10555-011-9279-y
Schindler, T., Grieger, F., Zak, A., Rorig, R., Konka, K., Ellsworth, A., & Crandall, C. (2020). Patient preferences when searching for clinical trials and adherence of study records to clinicaltrials.gov guidance in key registry data fields. PLoS One, 15(5), e0233294. https://doi.org/10.1371/journal.pone.0233294
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011). Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science, 331(6024), 1565-1570. https://doi.org/10.1126/science.1203486
Shimizu, M., Fukutomi, Y., Ninomiya, M., Nagura, K., Kato, T., Araki, H., & Moriwaki, H. (2008). Green tea extracts for the prevention of metachronous colorectal adenomas: A pilot study. Cancer Epidemiology Biomarkers & Prevention, 17(11), 3020-3025. https://doi.org/10.1158/1055-9965.epi-08-0528
Si, C., Gao, J., & Ma, X. (2024). Natural killer cell-derived exosome-based cancer therapy: From biological roles to clinical significance and implications. Molecular Cancer, 23(1). https://doi.org/10.1186/s12943-024-02045-4
Siegfried, N., Clarke, M., & Volmink, J. (2005). Randomised controlled trials in Africa of HIV and AIDS: Descriptive study and spatial distribution. BMJ, 331(7519), 742. https://doi.org/10.1136/bmj.331.7519.742
Smith, H., & Kang, Y. (2013). The metastasis-promoting roles of tumor-associated immune cells. Journal of Molecular Medicine, 91(4), 411-429. https://doi.org/10.1007/s00109-013-1021-5
Smith, J., Brown, L., & Johnson, K. (2023). PI3K/Akt pathway inhibition in cancer therapy. Nature Reviews Cancer, 23(7), 445-460.
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249. https://doi.org/10.3322/caac.21660
Suzuki, K., Yamamoto, T., & Nakamura, S. (2022). Immune cell recruitment in tumor microenvironment. Cancer Immunology Research, 10(8), 956-968.
Swann, J., & Smyth, M. (2007). Immune surveillance of tumors. Journal of Clinical Investigation, 117(5), 1137-1146. https://doi.org/10.1172/jci31405
Tanaka, M., Liu, X., & Yamamoto, S. (2021). Rb pathway modulation in cell cycle control. Molecular Cell, 81(9), 1890-1903.
Thompson, R., Davis, M., & Wilson, P. (2020). NK cell activation mechanisms. Nature Immunology, 21(12), 1456-1467.
Valenzuela, L., Antón, P., Tango, A., Gómez, F., Fulladosa, X., Carvalho, A., & Torrás, J. (2021). Avoiding immunogenic drugs is key to preserve renal function in patients receiving immune checkpoint inhibitors: Lessons learned from three illustrative cases. Journal of Onco-Nephrology, 5(3), 172-177. https://doi.org/10.1177/23993693211048506
Wall, M. E., & Wani, M. C. (1995). Camptothecin and taxol: Discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Research, 55(4), 753-760. https://doi.org/10.1158/0008-5472.CAN-95-0479
Wang, L., Chen, Y., & Zhang, M. (2023). VEGF signaling in tumor angiogenesis. Angiogenesis, 26(3), 234-248.
Weaver, B. A. (2014). How Taxol/paclitaxel kills cancer cells. Molecular Biology of the Cell, 25(18), 2677-2681. https://doi.org/10.1091/mbc.e14-04-0916
Xiong, Y., Wang, K., Zhou, H., Peng, L., You, W., & Fu, Z. (2018). Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression‐based study. Cancer Medicine, 7(9), 4496-4508. https://doi.org/10.1002/cam4.1745
Yamada, S., Yazawa, M., Yamamoto, M., Koitabashi, K., Ichikawa, D., Koike, J., & Shibagaki, Y. (2019). A case of biopsy-proven oxaliplatin-induced acute tubulointerstitial nephritis with thrombocytopenia and anemia. CEN Case Reports, 8(3), 188-193. https://doi.org/10.1007/s13730-019-00390-8
Yamamoto, H., Tanaka, Y., & Lee, K. (2023). DNA damage response pathways in cancer. Cell Reports, 42(4), 112-125.
Ye, L., Pang, W., Huang, Y., Wu, H., Huang, X., Liu, J., & Liu, J. (2021). Lansoprazole promotes cisplatin‐induced acute kidney injury via enhancing tubular necroptosis. Journal of Cellular and Molecular Medicine, 25(5), 2703-2713. https://doi.org/10.1111/jcmm.16302
Yun, D., Jang, M., An, J., Lee, J., Kim, D., Chin, H., & Han, S. (2019). Effect of steroids and relevant cytokine analysis in acute tubulointerstitial nephritis. BMC Nephrology, 20(1). https://doi.org/10.1186/s12882-019-1277-2
Zakiyanov, O., Ḉaḡlar, Y., Ryšavá, R., Jančová, E., Maixnerová, D., Frausová, D., & Chábová, V. (2023). Clinical features, outcomes, and response to corticosteroid treatment of acute tubulointerstitial nephritis: A single-centre retrospective cohort study in the Czech Republic. Kidney and Blood Pressure Research, 49(1), 1-8. https://doi.org/10.1159/000535415
Zhang, H., Wang, Y., & Chen, L. (2023). Apoptotic pathway activation in cancer therapy. Cell Death & Differentiation, 30(6), 1456-1470.
Zhang, W., Zhang, Y., Tang, J., Wang, X., Meng, C., Ji, W., & Li, J. (2025). The changing landscape of heart failure drug clinical trials in China, 2013–2023. Drug Design Development and Therapy, 19, 2597-2608. https://doi.org/10.2147/dddt.s511608
Zhou, S., Su, T., Xie, J., Xie, Q., Wang, L., Hu, Y., & Li, Y. (2023). Genome-wide association study in acute tubulointerstitial nephritis. Journal of the American Society of Nephrology, 34(5), 895-908. https://doi.org/10.1681/asn.0000000000000091
Zhu, L., Kalimuthu, S., Gangadaran, P., Oh, J., Lee, H., Baek, S., & Ahn, B. (2017). Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics, 7(10), 2732-2745. https://doi.org/10.7150/thno.18752
Zitvogel, L., Apétoh, L., Ghiringhelli, F., André, F., Tesnière, A., & Kroemer, G. (2008). The anticancer immune response: Indispensable for therapeutic success? Journal of Clinical Investigation, 118(6), 1991-2001. https://doi.org/10.1172/jci35180
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Igor Bombushkar, Anatoliy Gozhenko, Walery Zukow
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 265
Number of citations: 0
